| pubmed-article:7750279 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7750279 | lifeskim:mentions | umls-concept:C0441833 | lld:lifeskim |
| pubmed-article:7750279 | lifeskim:mentions | umls-concept:C0015385 | lld:lifeskim |
| pubmed-article:7750279 | lifeskim:mentions | umls-concept:C0009905 | lld:lifeskim |
| pubmed-article:7750279 | lifeskim:mentions | umls-concept:C0011155 | lld:lifeskim |
| pubmed-article:7750279 | lifeskim:mentions | umls-concept:C1744681 | lld:lifeskim |
| pubmed-article:7750279 | lifeskim:mentions | umls-concept:C0004083 | lld:lifeskim |
| pubmed-article:7750279 | lifeskim:mentions | umls-concept:C0392747 | lld:lifeskim |
| pubmed-article:7750279 | lifeskim:mentions | umls-concept:C0449774 | lld:lifeskim |
| pubmed-article:7750279 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7750279 | pubmed:dateCreated | 1995-6-22 | lld:pubmed |
| pubmed-article:7750279 | pubmed:abstractText | A case-control study on different groups of isolated congenital limb deficiency was performed in a ten-year population-based and revised Hungarian data set. A higher rate of one contraceptive pill type with relatively high dose (ethynodiol diacetate 1.0 mg + ethinyloestradiol 0.05 mg) used in the periconceptional period was found in the mothers of cases with terminal transverse defect (adjusted relative odds 1.9 with 95% confidence interval of 1.1-3.4). This risk is minimised by the use of recent low-dose pills. | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7750279 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7750279 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7750279 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7750279 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:7750279 | pubmed:issn | 0010-7824 | lld:pubmed |
| pubmed-article:7750279 | pubmed:author | pubmed-author:CzeizelA EAE | lld:pubmed |
| pubmed-article:7750279 | pubmed:author | pubmed-author:KodajII | lld:pubmed |
| pubmed-article:7750279 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7750279 | pubmed:volume | 51 | lld:pubmed |
| pubmed-article:7750279 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7750279 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7750279 | pubmed:pagination | 19-24 | lld:pubmed |
| pubmed-article:7750279 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:7750279 | pubmed:otherAbstract | PIP: In Hungary, researchers analyzed 1975-1984 population-based and revised data on 537 children with isolated congenital limb deficiency (CLD) (i.e., cases with at least 1 affected limb) and data on 537 age-matched controls with no CLD. They wanted to determine the association between periconceptional use of oral contraceptives (OCs) and CLD. Personal examination and/or medical documents confirmed reported diagnoses. They separated the isolated CLD cases into terminal transverse CLD, amniogenic CLD, radial and tibial CLD, ulnar-fibular CLD, split hand and/or foot CLD, and intercalary CLD. Periconceptional use of Bisecurin (relatively high dose of 1 mg ethynodiol diacetate and 0.05 mg ethinyl estradiol) was significantly associated with terminal transverse CLD (adjusted odds ratio [AOR] = 1.9; p = 0.03). It was also significantly associated with monomelic CLD (AOR = 1.6; 9.6% vs. 2.9%; p = 0.0015). The monomelic cases comprised 19 terminal transverse cases, 6 amniogenic cases, 7 radial cases, 3 atypical split hand cases, and 2 ulnar cases. 19 of the 20 terminal transverse cases were monomelic. Periconceptional use of Continuin (0.5 mg ethynodiol diacetate alone) was associated, but not significantly so, with terminal transverse CLD (6 cases vs. 1 control; p = 0.06). These findings suggest that use of OCs with a high dose of ethynodiol diacetate increases the risk of terminal transverse defect. Use of low dose OCs likely minimizes this risk. | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:meshHeading | pubmed-meshheading:7750279-... | lld:pubmed |
| pubmed-article:7750279 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7750279 | pubmed:articleTitle | A changing pattern in the association of oral contraceptives and the different groups of congenital limb deficiencies. | lld:pubmed |
| pubmed-article:7750279 | pubmed:affiliation | Department of Human Genetics and Teratology, National Institute of Hygiene, Budapest, Hungary. | lld:pubmed |
| pubmed-article:7750279 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7750279 | lld:pubmed |
